Newellis Inc (NUWE) 시세

Any word from Management how they will increase shareholder value?

How about stop the bleeding?

$1.40s + 20% low float 1m pump time news was good higher rate with Medicare aid so revenues will be higher this quarter 

$1.30 regained complainace few weeks back and device reimbursement Medicare/aid

NUWE.........................https://stockcharts.com/h-sc/ui?s=NUWE&p=W&b=5&g=0&id=p86431144783

restart soon

$2.25- + 23% ..2:40- 2.83 zone of interest breaks 2.83 gets interesting 

NUWE...................................https://stockcharts.com/h-sc/ui?s=NUWE&p=W&b=5&g=0&id=p86431144783

$2.30 + 24% NUWE 10k out reimbursement from Medicare/aid 400% increase 

$NUWE )2.18 + 20% Looks good a flip to $4 if gets going 

NUWE, 10Q due 11/11

Will see $8s here in time .Nice dip $1.60s today added ..this one takes off again after Nov 4th news  Medicare Medicaid pay quadruples on Jan 1st.. 4x 
with the payment rate increasing to $1,639 a day from $413, Nuwellis said Monday in a statement.

The reassignment recognizes the effectiveness of the therapy for the treatment of fluid overload in heart

Have buys stops and short cover over $3.24. 

Close above $4

Thank you for 2.55. Loaded

Circuit Breaker $3.29

1.9 float?  

Back to the $2s heck was a $20 stock not long ago

Is this a good long term buy?

nuwe.........................https://stockcharts.com/h-sc/ui?s=NUWE&p=W&b=5&g=0&id=p86431144783

$1.80 + 25% Time to pump this low floater again next up 1.85- 1.99
2.14- 2.27

2.40-2.84

Haven’t been able to absorb offering since August 23 ..what’s the next catalyst ?

sale of 496,901 shares of the Company’s common stock at a price of $1.8450 per share of common stock in a registered direct offering priced at-the-market under Nasdaq rules.
In addition, in a concurrent private placement, the Company will issue to the investors warrants to purchase up to 496,901 shares of common stock. The warrants have an exercise price of $1.72 per share, will be exercisable immediately following the date of issuance and will

Buy high sell low

big catalyst coming up for this low floater
New Evidence on Aquadex Ultrafiltration Therapy to be Presented at HFSA 2024 Conference taking place September 27-30, 2024
https://ir.nuwellis.com/news-releases/news-release-details/new-evidence-aquadex-ultrafiltration-therapy-be-presented-hfsa

NUWE 52w low… $1

NUWE new 52 week low

NUWE new 52=week low

New 52w low…

the R / S is in.
board decided to go easy on us,,,,only a 1:35 split
had this stock for a few years...was already at split adjusted $140 / share.
some of these bios ive kept in the barn for toooo long.
think i will relieve myself of this turd today ,and save the $38 re _org fee

dont have hardly any pennies left last 18 months or so. this otc crap and its mm`s all suck.

few years back u could make money in pinks......but its a rigged game now ......with runners shorted down to garbage by late afternoon

could hold these for 2 1/2 days and bail years ago......no longer interested in trading against algos, where a medium bid or offer causes all mm`s to shift instantly.

good luck alll....STAY WITH LISTED STOCKS!!

NO ONE WANTS THIS...?? ....hahahahahahahahahahahahah
defr14 on may 17....says R/S as HIGH AS 1 for 70 to be voted on in annual mtg

nic3e

starting

As the overall market starts to drop… NUWE will thrive

I predict Im getting back in today :)

Any predictions?

I guess Im not a fan of issuing shares and doing RS approx every 2 years to comply w/ NASDAQ
Thi s year is the RS Year. per May 1, 2024 Proxy Statement

Keep an eye on this one?

$NUWE Chart from #DDAmanda - #1 Stock Screener :

Find Winners Early:



Z

nice

GOT OUT AT .3 TODAY BUT PLAN TO GET BACK IN AROUND .18??

Nuwellis, Inc. Announces First Quarter 2024 Financial ResultsNuwellis, Inc. Announces First Quarter 2024 Financial Results

Tue, May 7, 2024

https://finance.yahoo.com/news/nuwellis-inc-announces-first-quarter-120000903.html?guccounter=1&guce_referrer=aHR0cHM6Ly9kdWNrZHVja2dvLmNvbS8&guce_referrer_sig=AQAAABkXGl5nBDowplt7CUUbnRUbIEc9EdIJlYjwIvUTd0W2SVIKw0x9u__QaWxT8qI2-1mWxP8TPhc_mrpMBZoxJ0jklwvHpVt9C2gbJGOmKuaFtdP3Y7VwFSDB-lVwbcgF32mMwpFAAL-oukC9_f-Zolhy9jT5SPRD51AnFXe6vWxR

$NUWE

NUWE: No "don't blink' today???

Hold on

Once again the corrupt small hedge funds show up the next day on small stocks, that had run ups the past day, and turn on their grind down machines programs after they shorted the previous days highs, and profit off the scared little fliptards who sell out with their profits getting cut over night,if you want to beat the small wall street criminal hedge funds, you have to not be a wimp and sell out,and raise sell orders much higher,and let the scm bags get squeezed out of their corrupt short manipulation positions.

Im in at .15 - think Im gonna hold until .50... Not sure yet

Solid Day here, more to come...

Bought in at 0.18

Should test 0.30+

GhosT

holding until Monday EOD I think

Nuwellis Receives USPTO Notice of Patent Allowance for Innovative Pediatric CRRT Technology

May 02, 2024

Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company dedicated to transforming the lives of patients suffering from fluid overload, today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for a patent application related to its innovative pediatric Continuous Renal Replacement Therapy (CRRT) device branded Vivian™. This patent strengthens Nuwellis' intellectual property portfolio and paves the way for the development of novel technology designed to improve treatment options for critically ill children.
The patented technology focuses on a design feature that allows healthcare providers to switch seamlessly between stationary operation and “transport” or “ambulation” mode, enabling unprecedented patient mobility. This innovative feature offers unmatched flexibility, allowing clinicians to tailor treatment plans to the specific needs of each young patient.

"We are thrilled to receive this patent allowance from the USPTO," said Nestor Jaramillo, Jr., President and Chief Executive Officer of Nuwellis. “A core focus of our business strategy is developing novel technology and a strong IP portfolio. This innovative technology will empower healthcare providers with the ability to adapt treatment plans as needed, ultimately leading to improved patient care and outcomes for critically ill children and neonates.”

Nuwellis is currently developing a new, fully integrated pediatric continuous renal replacement therapy (CRRT) device designed to provide care for small babies and children. This development effort is funded in part by a $1.7 million grant from the National Institutes of Health (NIH). The company has partnered with Minneapolis-based research and development firm Koronis Biomedical Technologies Corporation (KBT), the grant recipient, in the design and development of a custom pediatric product that will enable clinicians to better care for babies with limited kidney function.

Nuwellis is committed to developing life-saving technologies specifically designed for the unique needs of pediatric patients. This patent allowance represents a significant advancement in the company's mission to revolutionize pediatric fluid management.

About Nuwellis
Nuwellis, Inc. (Nasdaq: NUWE) is a medical technology company dedicated to transforming the lives of patients suffering from fluid overload through science, collaboration, and innovation. The company is focused on commercializing the Aquadex SmartFlow® system for ultrafiltration therapy. Nuwellis is headquartered in Minneapolis, with a wholly owned subsidiary in Ireland. For more information visit www.nuwellis.com or visit us on LinkedIn or Twitter.

About the Aquadex SmartFlow® System
The Aquadex SmartFlow system delivers clinically proven therapy using a simple, flexible and smart method of removing excess fluid from patients suffering from hypervolemia (fluid overload). The Aquadex SmartFlow system is indicated for temporary (up to 8 hours) or extended (longer than 8 hours in patients who require hospitalization) use in adult and pediatric patients weighing 20 kg or more whose fluid overload is unresponsive to medical management, including diuretics. All treatments must be administered by a health care provider, within an outpatient or inpatient clinical setting, under physician prescription, both having received training in extracorporeal therapies.

https://ih.advfn.com/stock-market/NASDAQ/newellis-NUWE/stock-news/93767856/nuwellis-receives-uspto-notice-of-patent-allowance

$NUWE

I am holding for tomorrow

Flippers and profit takers. Ill guess 3 of these as this stedy climbs untill financials, guessing other news will follow the report

Guessing a better report than was anticipated??